Welcome to our dedicated page for Boston Scien Cp SEC filings (Ticker: BSX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Boston Scientific Corporation filings document the regulatory record of a global medical technology company with device and therapy portfolios for cardiovascular, respiratory, digestive, oncological, neurological and urological conditions. Recent 8-K reports furnish operating results, clinical-trial announcements and other material events tied to products such as WATCHMAN and EKOS.
Proxy and governance filings cover director elections, executive compensation, stockholder votes, board committee matters and amendments to the company’s certificate of incorporation. Additional disclosures address capital resources and financing arrangements, including revolving credit terms, along with common-stock reporting, senior debt references, risk-related governance and formal exhibits filed under the Exchange Act.
Boston Scientific director Cheryl Pegus bought 1,770 shares of common stock in an open-market transaction. The purchase occurred at a weighted average price of about $56.49 per share, across multiple trades priced between $56.49 and $56.5009. After this transaction, she directly owns 1,770 shares.
BOSTON SCIENTIFIC CORP director Edward J. Ludwig made an open-market purchase of 3,580 shares of Common Stock at $56.68 per share. The transaction occurred on May 20, 2026 and increased his direct ownership to 25,359 shares following the trade.
Boston Scientific Corp director David C. Habiger reported buying additional company stock in two recent open-market transactions. He purchased 2,200 shares of Common Stock on May 19, 2026 at a weighted average price of $56.9451 per share, and 2,250 shares on May 20, 2026 at a weighted average price of $55.9195 per share. According to the filing, individual trades on each day occurred within narrow price ranges around these averages. Following these purchases, Habiger directly owns 13,878 Boston Scientific common shares.
Boston Scientific Corporation has entered into a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank as part of its previously announced $5 billion share repurchase authorization. The company will initially receive shares equal to 80% of the repurchase price, or about 30.4 million shares, based on the May 15, 2026 closing price of $52.68 per share. The final number of shares will be set using the volume‑weighted average price of the stock during the ASR term, less a discount, with settlement expected by June 30, 2026. After this transaction, $3 billion will remain available under the authorization, and management expects the ASR to add $0.02 to adjusted earnings per share for full‑year 2026 versus prior guidance.
Boston Scientific Corporation has entered into a $2 billion accelerated share repurchase (ASR) agreement with JPMorgan Chase Bank as part of its previously announced $5 billion share repurchase authorization. The company will initially receive shares equal to 80% of the repurchase price, or about 30.4 million shares, based on the May 15, 2026 closing price of $52.68 per share. The final number of shares will be set using the volume‑weighted average price of the stock during the ASR term, less a discount, with settlement expected by June 30, 2026. After this transaction, $3 billion will remain available under the authorization, and management expects the ASR to add $0.02 to adjusted earnings per share for full‑year 2026 versus prior guidance.
Boston Scientific Corporation has made a major strategic investment in MiRus LLC, a private developer of cardiovascular and orthopedic technologies, including the SIEGEL transcatheter aortic valve replacement (TAVR) system. The company paid $1.5 billion in cash for non-voting equity and an exclusive option on the TAVR business.
The investment gives Boston Scientific 33.75% of MiRus on a fully diluted basis and a Call Option to acquire 100% of a new MiRus subsidiary holding the TAVR assets for additional aggregate cash payments totaling $3.0 billion, contingent on clinical and regulatory milestones. MiRus may also receive future sales-based payments if the option is exercised.
The SIEGEL TAVR valve uses a proprietary nickel-free rhenium alloy, dry porcine tissue leaflets and an 8 French delivery system designed to reduce vascular complications. MiRus has begun the STAR pivotal trial in up to 1,025 severe aortic stenosis patients. Boston Scientific expects the MiRus investment to be immaterial to its adjusted earnings per share in 2026.
Boston Scientific Corporation has made a major strategic investment in MiRus LLC, a private developer of cardiovascular and orthopedic technologies, including the SIEGEL transcatheter aortic valve replacement (TAVR) system. The company paid $1.5 billion in cash for non-voting equity and an exclusive option on the TAVR business.
The investment gives Boston Scientific 33.75% of MiRus on a fully diluted basis and a Call Option to acquire 100% of a new MiRus subsidiary holding the TAVR assets for additional aggregate cash payments totaling $3.0 billion, contingent on clinical and regulatory milestones. MiRus may also receive future sales-based payments if the option is exercised.
The SIEGEL TAVR valve uses a proprietary nickel-free rhenium alloy, dry porcine tissue leaflets and an 8 French delivery system designed to reduce vascular complications. MiRus has begun the STAR pivotal trial in up to 1,025 severe aortic stenosis patients. Boston Scientific expects the MiRus investment to be immaterial to its adjusted earnings per share in 2026.
Zane Ellen M reported acquisition or exercise transactions in this Form 4 filing.
BOSTON SCIENTIFIC CORP director Ellen M. Zane received an annual equity award of common stock. She was granted 3,800 shares of restricted stock on May 7, 2026 at no cash cost per share. The award reflects a value of $215,000 divided by the closing price of the common stock on the grant date and will vest in full at the next annual meeting of stockholders. After this grant, she directly holds 27,934 common shares.
WICHMANN DAVID S reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director David S. Wichmann received an annual equity award of 3,800 shares of Common Stock on May 7, 2026. The grant was made at no cash cost to him and is structured as restricted stock that vests in full at the next annual stockholders’ meeting.
After this award, he directly owns 45,382 shares. The filing notes the grant reflects a value of $215,000, calculated by dividing that amount by the closing price of Boston Scientific’s common stock on the grant date.
Boston Scientific director Christophe Pierre Weber reported equity-based compensation grants. On May 7, 2026, he received 1,140 shares of restricted stock in lieu of 80% of his yearly cash retainer, reflecting a value of approximately $100,000 based on the grant-date closing price.
He also received an annual equity award of 1,767 restricted shares, tied to a program value of $215,000, with $64,500 representing 30% of that award. In addition, he was granted 2,660 Deferred Stock Units, tied to $150,500 (70% of the annual equity award), which convert into common shares after his service on the board ends. All equity awards vest in full at the next annual meeting of stockholders.
Smith Cathy R reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Cathy R. Smith received equity compensation in the form of deferred stock units. On 2026-05-07, she was granted 2,209 deferred stock units tied to common stock as an annual equity award valued at $215,000, plus 3,800 additional deferred stock units granted in lieu of $125,000 of yearly cash compensation.
Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock. Both awards vest in full at the next annual meeting of stockholders, with shares delivered only after she leaves the Board under the Non-Employee Director Deferred Compensation Plan. Following these grants, reported deferred stock unit balances in the respective plans were 6,888 and 4,679 units.
Pegus Cheryl reported acquisition or exercise transactions in this Form 4 filing.
Boston Scientific director Cheryl Pegus received two compensation grants of deferred stock units, not open-market purchases or sales. On May 7, 2026, she was awarded 3,800 deferred stock units representing an annual equity award valued at $215,000, based on the closing share price that day. She also received 1,281 deferred stock units granted in lieu of 50% of her yearly cash and committee chair retainers, reflecting a value of $72,500 divided by the same closing price. Each deferred stock unit represents a commitment to issue one share of Boston Scientific common stock, vesting in full at the next annual stockholders’ meeting, with shares delivered after she leaves Board service under the Non-Employee Director Deferred Compensation Plan. Following these awards, she directly holds 10,998 deferred stock units.